Summary of Alexandria Real Estate Equities (ARE) Q1 2026 Earnings Call

1Key Financial Results and Metrics

Funds from Operations (FFO) per Share: $1.73 for Q1 2026; reaffirmed guidance for 2026 at a midpoint of $6.40.

Leasing Volume: 647,000 square feet for the quarter, a decline attributed to lower renewals and no public biotech leases, which account for 24% of annual rental revenue.

Occupancy Rate: 87.7%, down 320 basis points from the previous quarter, primarily due to 657,000 square feet of lease expirations.

Same-Property Net Operating Income (NOI): Down 11.9% year-over-year, with a revised guidance range for 2026 indicating a decline of 9.5%.

General and Administrative Expenses: Reduced by $7.4 million compared to the 2024 quarterly average, with a full-year guidance range of $134 million to $154 million for 2026.

2Strategic Updates and Business Highlights

Balance Sheet Management: Continued focus on maintaining a strong and flexible balance sheet; $366 million gain from an unsecured bond tender reduced overall debt.

Leasing Strategy: Executed development and redevelopment leases totaling 394,000 square feet; focus on improving occupancy and NOI through leasing efforts.

Dispositions: Targeting $2.9 billion in dispositions and sales of partial interest, with 80% pending or identified. A shift in strategy to hold onto some assets due to leasing interest was noted.

Tenant Base Quality: 55% of annual rental revenue comes from investment-grade or large-cap tenants, with an average remaining lease term of 7.5 years.

3Forward Guidance and Outlook

Leasing Expectations: Anticipating an uptick in leasing volume to around 900,000 square feet in Q2 2026.

Occupancy Guidance: Updated year-end 2026 occupancy guidance from 88.5% to 87%, reflecting reduced expectations for asset dispositions.

Same-Property NOI Guidance: Adjusted to a decline of 9.5% for 2026, down from an earlier estimate of 8.5%.

FFO Guidance: Midpoint for Q4 2026 FFO per share diluted adjusted revised to $1.45, down from $1.50.

4Bad News, Challenges, or Points of Concern

Leasing Environment: Notable absence of public biotech leases in Q1 2026, indicating a challenging leasing environment.

Occupancy Pressure: Expected further declines in occupancy due to additional lease expirations in 2026.

Regulatory Uncertainty: Ongoing leadership challenges at the FDA and NIH are impacting the biotech sector's confidence and capital deployment.

Market Conditions: The life science real estate market remains selective, with public biotech companies struggling to secure financing without data or milestones.

5Notable Q&A Insights

Tenant Behavior: There is a cautious approach from private biotech tenants regarding expansion and lease modifications due to FDA uncertainties and capital market conditions.

Asset Strategy Changes: Some assets previously considered for sale are being retained due to renewed leasing interest, particularly for advanced technology uses.

Future of AI in Real Estate: AI's impact on space needs remains neutral at this stage, with no significant shifts in tenant demand or lab-to-office ratios observed.

Market Sentiment: There is a mix of domestic and international capital interested in high-quality assets, indicating a potential shift towards safer investments in the real estate sector. Overall, ARE is navigating a challenging operating environment while maintaining a focus on strategic initiatives to enhance its portfolio and financial performance.